Drug interactions
Bazedoxifene-conjugated estrogens + Secobarbital
Severity: Moderate
Bazedoxifene-conjugated estrogens and Secobarbital: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Barbiturates induce hepatic CYP3A4 and glucuronidation and can lower estrogen and bazedoxifene exposure. This may reduce relief of menopausal symptoms and weaken endometrial protection.
What this interaction means in plain words
Bazedoxifene-conjugated estrogens and Secobarbital can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Bazedoxifene-conjugated estrogens belongs to Endocrine; Secobarbital belongs to Central Nervous System.
Why it happens
Barbiturate-mediated enzyme induction increases metabolic clearance of estrogens and bazedoxifene.
What to do
Monitor for recurrent vasomotor symptoms and unexpected uterine bleeding, and evaluate the endometrium if bleeding occurs. Consider an alternative hypnotic that does not induce enzymes.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bazedoxifene-conjugated estrogens and Secobarbital, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Bazedoxifene-conjugated estrogens
- Anastrozole + Bazedoxifene-conjugated estrogens Contraindicated
- Bazedoxifene-conjugated estrogens + Ospemifene Contraindicated
- Antithrombin alfa + Bazedoxifene-conjugated estrogens Major
- Antithrombin iii + Bazedoxifene-conjugated estrogens Major
- Bazedoxifene-conjugated estrogens + Bemiparin Major
- Bazedoxifene-conjugated estrogens + Carbamazepine Major
Other interactions of Secobarbital
- Calcium / magnesium / potassium / sodium oxybates + Secobarbital Contraindicated
- Doravirine + Secobarbital Contraindicated
- Elbasvir / grazoprevir + Secobarbital Contraindicated
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Secobarbital Contraindicated
- Isavuconazonium + Secobarbital Contraindicated
- Lonafarnib + Secobarbital Contraindicated
Frequently asked questions
Can I take Bazedoxifene-conjugated estrogens with Secobarbital?
MediHelp rates the interaction as moderate. Bazedoxifene-conjugated estrogens and Secobarbital can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Barbiturates induce hepatic CYP3A4 and glucuronidation and can lower estrogen and bazedoxifene exposure. This may reduce relief of menopausal symptoms and weaken endometrial protection.
How serious is the interaction between Bazedoxifene-conjugated estrogens and Secobarbital?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for recurrent vasomotor symptoms and unexpected uterine bleeding, and evaluate the endometrium if bleeding occurs. Consider an alternative hypnotic that does not induce enzymes.
What other medicines interact with Bazedoxifene-conjugated estrogens?
MediHelp also lists interactions of Bazedoxifene-conjugated estrogens with, for example, Anastrozole, Ospemifene, Antithrombin alfa. The full list is on the Bazedoxifene-conjugated estrogens page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.